SML4366

Lasmiditan hemisuccinate

≥98% (HPLC)

• Synonim(y): 2,4,6-Trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]benzamid hemisuccinate, 2,4,6-Trifluoro-N-[6-[(1-methylpiperidin-4-yl)carbonyl]pyridin-2yl]benzamide hemisuccinate, COL 144 hemisuccinate, COL-144 hemisuccinate, COL144 hemisuccinate, LY 573144 hemisuccinate, LY-573144 hemisuccinate, LY573144 hemisuccinate
• Wzór empiryczny (zapis Hilla): C₃₈H₃₆F₆N₆O₄·C₄H₆O₄
• Numer CAS: 439239-92-6
• Masa cząsteczkowa: 872.81
• UNSPSC Code: 12352200
• MDL number: MFCD31728527
• Assay: ≥98% (HPLC)
• Form: powder
• Storage condition: desiccated

Właściwości

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• drug control: USDEA Schedule V
• storage condition: desiccated
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: -10 to -25°C

Opis

Biochem/physiol Actions

Lasmiditan (COL-144 and LY573144) is an orally active, potent and selective high-affinity serotonin receptor 5-HT1F agonist (5-HT1F/1E Ki = 2.21/594 nM; 5-HT1A/B/C Ki >1 μM; 5-HT2A/B/C Ki >2 μM; 5-HT6/7 Ki >3 μM). Lasmiditan induces mitochondrial biogenesis (MB) in human glomerular endothelial cells and mouse glomerular endothelial cells (100 nM for 72h). Unlike the triptans, Lasmiditan is void of vasoconstrictor activity toward isolated human coronary arteries (up to 100 μM) or in anaesthetized female beagle dogs in vivo (4.13-11.13 mg/kg i.v.)

Disclaimer

Hygroscopic, Store with desiccant

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• pictograms: GHS08,GHS05,GHS07
• signalword: Danger
• hcodes: H302,H318,H336,H361fd
• pcodes: P202 - P261 - P280 - P301 + P312 - P305 + P351 + P338 - P308 + P313
• Hazard Classifications: Acute Tox. 4 Oral - Eye Dam. 1 - Repr. 2 - STOT SE 3
• target_organs: Central nervous system
• Klasa składowania: 11 - Combustible Solids